NP
CPRX

Nilsine Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Nilsine Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-134,253
Closed -$2.64M – 402
2025
Q3 		$2.64M Buy
134,253
+7,114
+6% +$146K 0.24% 100
2025
Q2 		$2.76M Buy
127,139
+71,890
+130% +$1.7M 0.28% 93
2025
Q1 		$1.34M Buy
55,249
+21,730
+65% +$489K 0.15% 146
2024
Q4 		$700K Buy
+33,519
New +$720K 0.07% 215

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nilsine Partners's CPRX Position: Q4 2025 in Review

Nilsine Partners sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 134,253 shares — an estimated $2.64M sold.

Nilsine Partners first reported a position in CPRX in Q4 2024 and held it in 4 quarters. The position peaked at $2.76M in Q2 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Nilsine Partners reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Nilsine Partners sold 134,253 Catalyst Pharmaceutical shares in Q4 2025, an estimated $2.64M.
  • Nilsine Partners first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 4 quarters.
  • Nilsine Partners's Catalyst Pharmaceutical position peaked at $2.76M in Q2 2025.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Nilsine Partners's 13F filing for Q4 2025, filed 15 Jan 2026.